Agios Pharma (AGIO) Reports Q4 Loss of $1.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Leerink Partners Remains Sidelined on Agios Pharma (AGIO) - PT to $56
February 19, 2016 7:30 AM ESTLeerink Partners maintained a Market Perform rating on Agios Pharma (NASDAQ: AGIO), and cut the price target to $56.00 (from $62.00), following the company's 4Q earnings call. AGIO provided a number of incremental pipeline updates. Leerink sees the announced AG-348 and AG-519 data at EHA in June and... More
